论文部分内容阅读
目的探讨替比夫定与拉米夫定治疗慢性乙型肝炎的疗效及安全性。方法 2008年2月至2009年2月符合入选标准的39例慢性乙型肝炎患者,分为替比夫定组22例,拉米夫定组17例观察两组临床疗效及安全性。结果替比夫定组完全应答率明显优于拉米夫定组,P<0.05,差异有统计学意义;替比夫定组肌酸激酶升高发生率22.72%,拉米夫定组肌酸激酶升高发生率5.88%。结论替比夫定具有疗效确切,不良反应轻微,是一种较为安全的抗乙肝病毒口服药物,可用于一线治疗。
Objective To investigate the efficacy and safety of telbivudine and lamivudine in the treatment of chronic hepatitis B. Methods From February 2008 to February 2009, 39 patients with chronic hepatitis B who met the inclusion criteria were divided into telbivudine group (n = 22) and lamivudine group (n = 17). The clinical efficacy and safety were observed in both groups. Results The response rate of telbivudine group was significantly better than that of lamivudine group, P <0.05, the difference was statistically significant; the incidence of creatine kinase increased in telbivudine group was 22.72% The incidence of kinases increased 5.88%. Conclusion Telbivudine has a definite curative effect with mild adverse reactions. It is a safe oral anti-hepatitis B virus drug and can be used in the first-line treatment.